Samsara BioCapital — 2017 Investments
3 investments dated 2017 · listed companies and verified rows first · show all
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Amir Nashat(Non-Management Director)Paul Schimmel(Non-Management Director)Akkaraju Srinivas(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)Ed Penhoet(Non-Management Director)
Board seatSrini Akkaraju· per SEC Form D · $45.8M raise · filed Sep 2017
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Alan Buckler(Executive Officer)Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)David Hallal(Director)Michael Gilman(Director)Jeffrey Flier(Director)
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Alejandro Dorenbaum(Executive Officer)Peter Moldt(Director)Christopher Bebbington(Executive Officer, Director)
BoardFarah Champsi(Director)John McKearn(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.